MedTrace Logo

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

NCT00029328 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-03-25

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell transplantation.

Conditions

  • Respiratory Distress Syndrome, Adult
  • Bronchiolitis Obliterans
  • Pneumonia

Interventions

DRUG

etanercept

Sponsors & Collaborators

  • FDA Office of Orphan Products Development

    lead FED

Principal Investigators

  • Kenneth Cooke, M.D. · University of Michigan, Ann Arbor, MI

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
12 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Completion
2003-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00029328 on ClinicalTrials.gov